Kindred Biosciences may develop drugs for pets, but the company's December IPO has been anything but a dog. The stock has more than doubled since it started trading, but the company's employees are hard at work developing its osteoarthritis drug which CEO Dr. Richard Chin expects to be on the market by 2015. Chin says the company raised sufficient cash to be cash flow positive in the next 3 years and he expects up to 3 product launches in that time. As for a potential tie-up with fellow animal health provider Zoetis, Chin says Kindred is concentrating on being a stand alone company for now.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.